Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II).
Peck-Radosavljevic M, Angermayr B, Datz C, Ferlitsch A, Ferlitsch M, Fuhrmann V, Häfner M, Kramer L, Maieron A, Payer B, Reiberger T, Stauber R, Steininger R, Trauner M, Thurnher S, Ulbrich G, Vogel W, Zoller H, Graziadei I; Austrian Society of Gastroenterology and Hepatology. Peck-Radosavljevic M, et al. Among authors: datz c. Wien Klin Wochenschr. 2013 Apr;125(7-8):200-19. doi: 10.1007/s00508-013-0337-z. Epub 2013 Apr 12. Wien Klin Wochenschr. 2013. PMID: 23579878
Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
Ferenci P, Stauber R, Propst A, Fiedler R, Müller C, Gschwantler M, Schütze K, Datz C, Judmaier G, Vogel W, Krejs GJ, Gangl A. Ferenci P, et al. Among authors: datz c. Dig Dis Sci. 1996 Dec;41(12 Suppl):103S-108S. doi: 10.1007/BF02087884. Dig Dis Sci. 1996. PMID: 9011466 Clinical Trial.
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis.
Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, Ludwiczek O, Shawcross D, Zoller H, Alisa A, Mookerjee RP, Graziadei I, Datz C, Trauner M, Schuppan D, Obrist P, Vogel W, Williams R. Tilg H, et al. Among authors: datz c. J Hepatol. 2003 Apr;38(4):419-25. doi: 10.1016/s0168-8278(02)00442-7. J Hepatol. 2003. PMID: 12663232 Clinical Trial.
Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
Steindl-Munda P, Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, Stauber R, Hackl F, Jessner W, Rosenbeiger M, Gangl A, Vogel W; Austrian Hepatitis Study Group. Steindl-Munda P, et al. Among authors: datz c. Liver Int. 2003 Aug;23(4):269-75. doi: 10.1034/j.1600-0676.2003.00838.x. Liver Int. 2003. PMID: 12895267 Clinical Trial.
Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
Stauber RE, Hofer H, Hackl F, Schütze K, Datz C, Hegenbarth K, Jessner W, Steindl-Munda P, Peter F; Austrian Hepatitis Study Group. Stauber RE, et al. Among authors: datz c. Wien Klin Wochenschr. 2004 Aug 31;116(15-16):530-5. doi: 10.1007/BF03217706. Wien Klin Wochenschr. 2004. PMID: 15471180 Clinical Trial.
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K; Austrian Hepatitis Study Group. Ferenci P, et al. Hepatology. 2008 Jun;47(6):1816-23. doi: 10.1002/hep.22262. Hepatology. 2008. PMID: 18454510 Clinical Trial.
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P; Austrian Hepatitis Study Group. Ferenci P, et al. Among authors: datz c. Gastroenterology. 2008 Aug;135(2):451-8. doi: 10.1053/j.gastro.2008.04.015. Epub 2008 May 27. Gastroenterology. 2008. PMID: 18503773 Clinical Trial.
192 results